NHS England to Reimburse AstraZeneca's Enhertu for HER2-Low Breast Cancer After US-UK Pricing Deal
- Enhertu (trastuzumab deruxtecan), an AstraZeneca/Daiichi Sankyo HER2-targeting antibody-drug conjugate, will now be reimbursed by NHS England for HER2-low metastatic breast cancer.
- The move reverses NICE's July 2024 rejection of the drug for this indication, ending a years-long access dispute.
- It follows a new NICE agreement made possible by a broader U.S.-U.K. drug pricing deal (announced December 2025), which raised NICE's cost-effectiveness thresholds from about £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year.
- A new quality-of-life assessment methodology, published August 27, 2026, also supported the reassessment.
- About 1,000 women a year in England with HER2-low metastatic breast cancer are expected to now qualify, with studies reporting an average survival gain of roughly six months.
The science and data here are unchanged from NICE's 2024 rejection — this is a payer-economics win, not a clinical one, and it's easy to conflate the two. What actually moved was NICE's cost-effectiveness ceiling, from roughly £20-30K to £25-35K per QALY, engineered by the broader US-UK pricing deal, not new trial results. That's the real story: the first tangible commercial outcome traceable to that trade agreement, and it hands every company with a NICE-rejected asset a concrete playbook for reopening the case. Commercially, ~1,000 patients/year in England is a rounding error for AZ/Daiichi's global Enhertu franchise — the payoff is precedent, not revenue. Watch for ripple effects: rival ADCs and other HER2-low contenders now face a materially easier cost-effectiveness bar, reshaping competitive dynamics in an increasingly crowded ADC pipeline.
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal ↗